Publications by authors named "Susan Chuck"

Claim this Profile
B
Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age.
Franco Maggiolo, Giuliano Rizzardini, Jean-Michel Molina, Federico Pulido, Stephane De Wit, Susan K Chuck

HIV Med· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials.
Chloe Orkin, Faiza Ajana, Cissy Kityo, Ellen Koenig, Eva Natukunda, Susan K Chuck

J Acquir Immune Defic Syndr· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial.
Franco Maggiolo, Giuliano Rizzardini, Jean-Michel Molina, Federico Pulido, Stephane De Wit, Susan K Chuck

Infect Dis Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen.
Giuliano Rizzardini, Andrea Gori, Celia Miralles, Julián Olalla, Jean-Michel Molina, Susan K Chuck

AIDS· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide.
Joseph M Custodio, Susan K Chuck, Hoa Chu, Huyen Cao, Grace Ma

Pharmacol Res Perspect· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
Ed L Wilkins, Calvin J Cohen, Benoit Trottier, Stefan Esser, Don E Smith, Susan Chuck

AIDS Care· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study.
Danielle P Porter, Jonathan Toma, Yuping Tan, Owen Solberg, Suqin Cai, Susan K Chuck

HIV Clin Trials· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study.
Jan van Lunzen, Andrea Antinori, Calvin J Cohen, José R Arribas, David A Wohl, Susan K Chuck

AIDS· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.
Calvin Cohen, David Wohl, Jose R Arribas, Keith Henry, Jan Van Lunzen, Susan Chuck

AIDS· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.
Georg Behrens, Bart Rijnders, Mark Nelson, Chloe Orkin, Calvin Cohen, Susan K Chuck

AIDS Patient Care STDS· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
Anthony M Mills, Calvin Cohen, Edwin Dejesus, Cynthia Brinson, Scott Williams, Susan K Chuck

HIV Clin Trials· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients.
Ighovwerha Ofotokun, Susan K Chuck, Brian Schmotzer, Kelly L O'Neil

AIDS Res Ther· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsules.
Shannon Schrader, Susan K Chuck, Laurie W Rahn, Paras Parekh, Katherine G Emrich

AIDS Res Ther· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lopinavir/Ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy.
Ighovwerha Ofotokun, Susan K Chuck, Jose N Binongo, Mauricio Palau, Jeffrey L Lennox

J Clin Pharmacol· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiretroviral pharmacokinetic profile: a review of sex differences.
Ighovwerha Ofotokun, Susan K Chuck, Jane E Hitti

Gend Med· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of protease inhibitor-associated hyperlipidemia.
Scott R Penzak, Susan K Chuck

Am J Cardiovasc Drugs· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Collaborative drug therapy management by pharmacists--2003.
Raymond W Hammond, Amy H Schwartz, Marla J Campbell, Tami L Remington, Susan Chuck

Pharmacotherapy· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk-benefit of HMG-CoA reductase inhibitors in the treatment of HIV protease inhibitor-related hyperlipidaemia.
Susan K Chuck, Scott R Penzak

Expert Opin Drug Saf· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis